← The Wire
FULCNasdaq
Fulcrum Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1680581
Develops small molecules for rare genetic diseases, including sickle cell disease with its candidate Pociredir
red 8-K · 90d⚡ Elevated coverage
$230M
Market cap
$3.73
Last close
-1.8%
1D
-1.1%
5D
1.5M
Volume
Price · last 39 sessions-46.9%
May 4L $3.14 · H $7.25Jun 29
162
Total filings
Jun 25, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 25, 20268-KExecutive ChangeJun 11, 20268-KExit / Disposal Costs · Company UpdateJun 4, 20268-KCompany UpdateJun 1, 2026DEFA14ADEFA14AApr 30, 2026DEF 14ADEF 14AApr 30, 202610-Q10-QApr 27, 20268-KExecutive Change · Agreement TerminatedApr 27, 202610-K10-KFeb 24, 20268-KResults of OperationsFeb 24, 20268-KResults of Operations · Reg FD DisclosureJan 12, 20268-KMaterial Agreement · Company UpdateDec 11, 2025424B5424B5Dec 11, 2025424B5424B5Dec 8, 20258-KReg FD Disclosure · Company UpdateDec 8, 202510-Q10-QOct 29, 20258-KResults of OperationsOct 29, 20258-KReg FD DisclosureAug 28, 202510-Q10-QJul 29, 20258-KResults of Operations · Company UpdateJul 29, 20258-KShareholder VoteJun 27, 202510-Q10-QMay 1, 20258-KResults of OperationsMay 1, 2025DEFA14ADEFA14AApr 30, 2025DEF 14ADEF 14AApr 30, 20258-KAgreement TerminatedMar 4, 202510-K10-KFeb 25, 20258-KResults of OperationsFeb 25, 20258-KResults of Operations · Reg FD DisclosureJan 13, 20258-KAgreement TerminatedDec 23, 2024SC 13GSC 13GDec 6, 202410-Q10-QNov 13, 20248-KResults of OperationsNov 13, 20248-KExecutive ChangeNov 12, 2024SC 13GSC 13GNov 8, 2024SC 13GSC 13GOct 21, 20248-KExit / Disposal CostsSep 24, 2024SC 13GSC 13GSep 20, 20248-KCompany UpdateSep 12, 20248-KEquity IssuanceAug 22, 202410-Q10-QJul 31, 20248-KResults of OperationsJul 31, 20248-KExecutive Change · Shareholder VoteJun 17, 202410-Q10-QMay 13, 20248-KMaterial Agreement · Results of OperationsMay 13, 2024DEFA14ADEFA14AApr 19, 2024DEF 14ADEF 14AApr 19, 202410-K10-KFeb 27, 20248-KResults of OperationsFeb 27, 202410-Q10-QNov 7, 20238-KResults of OperationsNov 7, 20238-KExecutive ChangeOct 2, 20238-KReg FD DisclosureAug 22, 202310-Q10-QAug 3, 20238-KExecutive Change · Results of OperationsAug 3, 20238-KMaterial AgreementJul 10, 202310-K/A10-K/AJun 26, 202310-K/A10-K/AJun 26, 202310-K/A10-K/AJun 23, 20238-KBylaw Amendment · Shareholder VoteJun 9, 202310-Q10-QMay 15, 20238-KExecutive Change · Results of OperationsMay 15, 2023DEFA14ADEFA14AApr 28, 2023DEF 14ADEF 14AApr 28, 20238-KExecutive ChangeApr 5, 202310-K10-KMar 9, 20238-KResults of OperationsMar 9, 2023SC 13GFULCRUM THERAPEUTICS, INC.Mar 6, 20238-KMaterial Agreement · Company UpdateJan 18, 2023424B5424B5Jan 18, 2023424B5424B5Jan 17, 20238-KResults of Operations · Company UpdateJan 17, 20238-KExecutive Change · Results of OperationsJan 4, 202310-Q10-QNov 8, 20228-KResults of OperationsNov 8, 20228-KExecutive ChangeOct 19, 2022SC 13GFULCRUM THERAPEUTICS, INC.Aug 26, 20228-KCompany UpdateAug 23, 20228-KMaterial Agreement · Company UpdateAug 17, 2022424B5424B5Aug 17, 2022
Insider Activity
In the 90 days to Feb 2, 2026: 3 sold $59.1M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 2, 2026 | Gould Robert JDirector | Sell | 15,000 | $10.72 | $161K |
| Jan 2, 2026 | Gould Robert JDirector | Sell | 15,000 | $11.87 | $178K |
| Jan 2, 2026 | Gould Robert JDirector | Sell | 15,000 | $10.87 | $163K |
| Dec 15, 2025 | Oltmans Curtis GaleChief Legal Officer | Sell | 3,452 | $12.92 | $45K |
| Dec 8, 2025 | Ra Capital Healthcare Fund LpTenPercentOwner | Sell | 2,706,397 | $14.28 | $38.6M |
| Dec 8, 2025 | Ra Capital Healthcare Fund LpTenPercentOwner | Sell | 1,377,020 | $13.33 | $18.4M |
| Dec 8, 2025 | Ra Capital Healthcare Fund LpTenPercentOwner | Sell | 91,722 | $14.98 | $1.4M |
| Nov 19, 2025 | Gould Robert JDirector | Sell | 15,000 | $11.03 | $165K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 3 reputable articles · skews ▼ negative.
MorningstarFULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations26d agoBarron'sThis Biotech Stock Plunges 54%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’27d agoReutersFulcrum plummets over 50% after scrapping lead sickle-cell drug on FDA concerns28d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance